en · de · es · fr · pt
epitalon-notes.peptides4800.com › Faq › Background And Chemical Identity — Worked Examples

Background And Chemical Identity — Worked Examples

By Editorial Desk · published 2025-08-25 · last reviewed 2025-09-27 · Faq

epithalamin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-27. Anything still debated is marked as such rather than presented as settled.

Background and Chemical Identity

Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.

Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.

Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.

Epitalon Background and Discovery

Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Epitalon at a glance

PropertyValueNotes
Amino acid sequenceAla-Glu-Asp-GlyLinear tetrapeptide, also written AEDG
Molecular massAbout 390.35 g/molValue calculated from the sequence
AppearanceWhite to off-white powderLyophilised material forms a loose cake
SolubilityFreely soluble in waterAlso dissolves in isotonic saline
Storage-20 °C, desiccatedAliquot solutions to avoid freeze–thaw cycling

Epitalon Background And Identification

The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.

Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.

Related pages on this site

Notes from published material

Essendon was fined $2 million, an Australian sporting record fine against a club. Essendon was ruled ineligible to compete in the 2013 AFL finals series, and would be relegated to finish ninth; (the club was on track to qualify for the finals in seventh place). Essendon was prohibited from exercising draft picks in two drafts: in 2013, its first and second-round draft picks were prohibited, and in 2014, it was prohibited from exercising the first and second-round draft picks it would have received based on its finishing position, but was granted the last draft pick in the first round. Senior coach James Hird was suspended from involvement in any football club for twelve months, effective 25 August 2013. Football operations manager Danny Corcoran was suspended from involvement in any football club for four months, with a further two-month suspended sentence, effective 1 October 2013. A fine of $30,000 was imposed on assistant coach Mark Thompson. Thompson personally paid $5,000 of the fine, with Essendon covering the balance. As part of the agreement, Hird dropped legal action that he had raised against the charges in the Supreme Court. Despite the connections between Essendon's AFL and VFL teams, the VFL team was still permitted to play in the VFL finals series. Club doctor Bruce Reid was also charged and issued a suspension. He announced he would contest the charges in the Supreme Court of Victoria, and on 18 September 2013, the AFL dropped the charges.

==== Non-selective ==== α-MSH β-MSH γ-MSH ACTH Afamelanotide Bremelanotide Melanotan II Modimelanotide Setmelanotide — MC4 receptor agonist which is FDA approved to help with chronic weight management in those with pathogenic (or uncertain) variants in POMC and certain related genes.

===== First generation ===== The Cronin–Gerow Implant, prosthesis model 1963, was a silicone rubber envelope-sac, shaped like a teardrop, which was filled with viscous silicone-gel. To reduce the rotation of the emplaced breast implant upon the chest wall, the model 1963 prosthesis was affixed to the implant pocket with a fastener-patch, made of Dacron material (polyethylene terephthalate), which was attached to the rear of the breast implant shell.

== Adverse reactions == The safety profile of cinoxacin appears to be rather unremarkable. Adverse drug reactions appear to be limited to the gastrointestinal system and the central nervous system. Hypersensitivity resulting in an anaphylactic reactions (as seen with all drugs found within this class) has also been reported in association with cinoxacin. Animal studies have shown that Cinoxacin is associated with renal damage. Such damage appears to be due to the physical trauma resulting from deposition of cinoxacin crystals in the urinary tract. Such crystaluria has also been reported with other drugs in this class. A review of the literature indicates that patients treated with cinoxacin reported fewer adverse drug reactions than those treated with nalidixic acid, furadantin, amoxicillin, or trimethoprim-sulfamethoxazole. Although phototoxicity and photoallergenicity is well demonstrated experimentally, phototoxicity does not appear to be an issue with cinoxacin As a result of this safety profile the manufacturer, Eli Lilley states that "cinoxacin perhaps should be reserved only for those patients with organisms resistant to usual first-line agents or those who fail to respond to therapy with these agents."

Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals. The most common side effects include infections, low levels of white blood cells, headache, cough, nausea (feeling sick), vomiting, diarrhea, constipation, tiredness, hair loss and rash. Ribociclib was approved for medical use in the United States in March 2017, in the European Union in August 2017, and in the United Kingdom in February 2021.

Sources: en.wikipedia.org

Background from the literature

Fialuridine (FIAU) is a synthetic, solid, fluorinated nucleoside analogue of thymidine that was investigated as a treatment for chronic hepatitis B virus infection (HBV) in the early 1990s. Its effectiveness was evaluated during a Phase II clinical trial over a six-month course, with 24 patients treated. FIAU was provided by Oclassen Pharmaceuticals and administered under an Investigational New Drug Application held by Eli Lilly and Company. Administration of FIAU resulted in antiviral activity, alongside several side effects which resulted in the termination of some clinical trials. Investigations found that affected patients suffered a depletion of mitochondrial DNA (mtDNA) in both liver and muscle tissue, establishing mitochondrial dysfunction as a contributing mechanism to toxicity. The FIAU trial is considered a landmark case in drug production and influenced subsequent drug safety assessments regarding mitochondrial toxicity.

== Cited sources == Vandenbosch, Robert & Vandenbosch, Susanne E. (2007). Nuclear waste stalemate. Salt Lake City: University of Utah Press. ISBN 978-0874809039. Hecker, Siegfried S. (2000). "The Plutonium Challenge-Environmental Issues". Los Alamos Science (26). Los Alamos National Laboratory: 36–47. Retrieved 1 October 2023.

=== Insulin glargine === Insulin glargine is a long-acting modified form of medical insulin used in the management of type 1 and type 2 diabetes. It is administered through subcutaneous injection. Its effects typically begin within an hour of injection. Common side effects include (hypoglycemia, issues at the injection site, itchiness, and weight gain. NPH insulin is generally preferred over insulin glargine during pregnancy. After injection, microcrystals gradually release insulin over a period of approximately 24 hours. This insulin works by facilitating the absorption of glucose by body tissues and reducing glucose production by the liver. Insulin glargine was patented, although the patent expired in most countries in 2014. It was approved for medical use in the United States in 2000. It is listed on the World Health Organization's List of Essential Medicines. In 2022, it ranked as the 28th most commonly prescribed medication in the United States, with more than 18 million prescriptions. In July 2021, the US Food and Drug Administration (FDA) approved an interchangeable biosimilar insulin product, Semglee (insulin glargine-yfgn), for the treatment of diabetes. Unbranded versions of insulin glargine and insulin glargine-yfgn are sold by Sanofi and Viatris.

== Former units == With the 2018 reforms, Specialist Corps other than the Transportation Corps have been placed under other ministries, while the China Coast Guard (CCG) was transferred from State Council to PAP command, and the Transportation Corps has some units under the Mobile Corps. The Border Defense Corps and Guards Corps have been absorbed by the Ministry of Public Security (MPS). The Forestry Corps were merged with the China Fire Services (also known as the firefighting corps) of the MPS and reorganised as China Fire and Rescue (CF&R), it was placed under the Ministry of Emergency Management. The Gold Corps and Hydropower Corps have been transformed into state-owned enterprises under the supervision of the relevant State Council ministries (Ministry of Natural Resources and China National Gold Group Corporation and China Aneng Construction Corporation, respectively).

Sources: en.wikipedia.org

Frequently asked questions

Is epitalon a natural substance?

It is a synthetic tetrapeptide. Its sequence was derived from research on peptide fractions of bovine pineal extract, and the intact AEDG sequence has not been demonstrated as an abundant free peptide in human tissue.

What does the abbreviation AEDG mean?

AEDG is the one-letter code for the four amino acids alanine, glutamate, aspartate and glycine in that order. The same molecule is written in three-letter form as Ala-Glu-Asp-Gly.

How is the identity of epitalon confirmed in a laboratory?

Identity is normally confirmed by mass spectrometry against the calculated mass of roughly 390.35 g/mol. Purity is then estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection.

What is epitalon made of?

It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.

Network